2024
DOI: 10.1101/2024.03.25.24304862
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

First Phase 1b, single-center, age de-escalation trial of theP. falciparumblood-stage malaria vaccine candidate RH5.1/Matrix-M: a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants

Sarah E. Silk,
Wilmina F. Kalinga,
Jo Salkeld
et al.

Abstract: Background RH5.1 is a soluble protein vaccine candidate for blood-stagePlasmodium falciparummalaria, previously trialed in healthy UK adults in combination with AS01Badjuvant. Here, RH5.1 was formulated with Matrix-M™ adjuvant to assess safety and immunogenicity in a malaria-endemic adult and pediatric population for the first time. Methods We conducted a Phase 1b, single-center, dose-escalation, age de-escalation, first-in-human trial of RH5.1/Matrix-M™ in Bagamoyo, Tanzania. Healthy adults (18-45 years) and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 34 publications
(70 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?